Latest receivables for 6492.TWO: $110K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), 6492.TWO shows a receivables of $110K. That compares with $130K in the prior-year period — down 16.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 6492.TWO's receivables is now $110K (was $130K) — a 16.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Senhwa Biosciences is outperforming or lagging.
Tracking 6492.TWO's receivables over time shows whether Senhwa Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $110K That compares with $130K in the prior-year period — down 16.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Senhwa Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $110K) with ownership activity and broader fundamentals.
Senhwa Biosciences's receivables is $110K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.